Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System Transfemoral and Transapical Delivery Systems), For the Treatment of Moderate to Severe Mitral Regurgitation Study
A study for patients with mitral regurgitation using study device CardiAQ Transcatheter Mitral Valve Implantation System
Sponsor: Edwards Lifesciences
Enrolling: Male and Female Patients
IRB Number: AAAQ5112
U.S. Govt. ID: NCT02515539
Contact: Martin Leon: 212-342-3617 / ml2398@cumc.columbia.edu
Additional Study Information: The goal of this study is to assess the safety and function of this new device to insert an artificial mitral valve. This study is for patients who are a high risk candidate for standard openheart surgery to treat their mitral regurgitation. The standard medical treatments generally available to patients with mitral regurgitation who do not undergo surgery may improve some of the symptoms, but will not fix the condition or cure their mitral regurgitation. Patients involved will be evaluated on how they are doing with the device and if the device is working as it supposed to.
This study is closed
Martin Leon, MD
Do You Qualify?
Do you have mitral regurgitation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Martin Leon